H.C. Wainwright Keeps a Buy Rating on Sarepta Therapeutics (SRPT)


H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics (SRPT) today and set a price target of $267. The company’s shares opened today at $151.99.

Chattopadhyay said:

“Our $267 price target is derived from a risk-adjusted (does not include CMT or Sanfilippo A) DCF analysis and is based on: beta of 1.51, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.0%, and tax rate of 15% beginning in FY 2024.”

According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.4% and a 47.8% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.

Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $202.62, a 33.3% upside from current levels. In a report issued on February 12, Nomura also reiterated a Buy rating on the stock with a $205 price target.

See today’s analyst top recommended stocks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $76.39 million. In comparison, last year the company had a GAAP net loss of $24 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare neuromuscular diseases. It focuses on the development of its potentially disease-modifying Duchenne Muscular Dystrophy drug candidates.

Read More on SRPT:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts